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The measles virus (MV) P gene encodes three proteins: P, an essential polymerase cofactor, and C and V, which have multiple functions
including immune evasion. We show here that the MV P protein also contributes to immune evasion, and that tyrosine 110 is required to block
nuclear translocation of the signal transducer and activator of transcription factors (STAT) after interferon type I treatment. In particular, MV P
inhibits STAT1 phosphorylation. This is shown not only by transient expression but also by reverse genetic analyses based on a new functional
infectious cDNA derived from a MV vaccine vial (Moraten strain). Our study also identifies a conserved sequence around P protein tyrosine 110
as a candidate interaction site with a cellular protein.
© 2006 Elsevier Inc. All rights reserved.Keywords: Measles virus; Phosphoprotein; Innate immunity; Interferon signalingIntroduction
Cytokine signal transduction is essential for normal immune
function and controls the quality of the host responses to
pathogenic microorganisms. Most cytokines trigger intracellular
signaling cascades involving one or more signal transducers and
activation of transcription (STAT) proteins. The interferon (IFN)
response is one of the principal defense mechanisms against
viral infection. The alpha and beta (type I) IFN (IFNα/β) family
is of primary importance for both innate and adaptive antiviral
immunity (Aaronson and Horvath, 2002; Samuel, 2001; Stark et
al., 1998). IFNα/β are synthesized and secreted by cells in direct
response to viral infection, and more specifically to viral pro-
ducts including double-stranded RNA. This triggers a cascade of
cytokine reactions that leads to the activation of cellular tran-
scription factors required for IFN synthesis (Fitzgerald et al.,
2003; Sharma et al., 2003).⁎ Corresponding author. Molecular Medicine Program, Mayo Clinic and
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doi:10.1016/j.virol.2006.09.049IFNα/β initiates a receptor-mediated signaling system that
activates the Janus kinase 1 (JAK1) and tyrosine kinase 2
(TYK2), which in turn phosphorylate STAT1 and STAT2
(Darnell, 1997). The phosphorylated STAT proteins hetero-
dimerize, associate with interferon regulatory factor 9 (IRF-9)
and produce an activated STAT1–STAT2–IRF9 heterotrimeric
transcription complex known as IFN-stimulated gene factor 3
(ISGF3) (Levy et al., 1989). The ISGF3 complex translocates to
the nucleus, where it binds to IFN-sensitive response elements
(ISRE) within the promoters of IFN stimulated genes, resulting
in transcriptional up-regulation of these genes and establish-
ment of an antiviral state (Darnell, 1997). Viruses have
developed many mechanisms to escape the antiviral action of
IFN (Samuel, 2001). For example, Paramyxoviruses not only
block the synthesis of IFNα/β, but also inhibit signal
transduction in response to IFNα/β by effecting the molecules
involved in the JAK/STAT pathway (Garcia-Sastre, 2002;
Hengel et al., 2005; Katze et al., 2002).
Paramyxoviruses are negative stranded RNA viruses with at
least six genes, five of which produce one protein (Lamb and
Kolakofsky, 2001). The sixth gene (P) encodes up to six
different proteins, which are accessed by different mechanisms
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(MV) encodes only three products: the phosphoprotein (P) and
proteins C and V. Of these, P is the only protein essential for
viral RNA synthesis. P is a polymerase cofactor whose reading
frame begins at the first AUG of the P mRNA (Bellini et al.,
1985). C has 186 amino acids and its reading frame is accessed
by alternative translation initiation (Bellini et al., 1985). V is
produced from edited mRNAs that have an additional
nucleotide (Cattaneo et al., 1989). V shares the first 231
amino acids with P and in addition has a 68 amino acids zinc-
binding cysteine-rich carboxyl-terminal domain highly con-
served between most Paramyxoviruses (Paterson et al., 1995).
The V protein of another paramyxovirus interacts with ubiquitin
ligase DDB1 through the conserved carboxyl terminal region
(Andrejeva et al., 2002; Li et al., 2006; Ulane and Horvath,
2002). In addition, it binds the IFN-inducible RNA helicase
mda-5 (Andrejeva et al., 2004).
Both MV C and V proteins modulate IFN signaling. Using a
recombinant MV that does not express the C protein and its
parental strain (MV Ed-Tag, original infectious cDNA), Shaffer
et al. showed that the C protein inhibits the production of
IFNα/β by human cells and also blocks IFNα/β signaling
(Radecke and Billeter, 1996; Radecke et al., 1995; Shaffer et
al., 2003). Using immunofluorescence and confocal analysis,
Palosaari et al. showed that V interferes with the nuclear
translocation of the STAT1 and STAT2 protein after IFN
treatment, but does not affect tyrosine phosphorylation. STAT3
nuclear import was also inhibited by expression of V protein
(Palosaari et al., 2003). MV infection alters the subcellular
localization of the STAT1 protein and concentrates it in
cytoplasmic bodies that contain also the MV nucleocapsid (N)
protein and RNA (Palosaari et al., 2003). In addition, MV V
interacts with the DNA binding domain of two p53 protein
family members (Cruz et al., 2006).
Since the C and V proteins not only interfere with the
cytokine response but also perform other tasks, it is important to
characterize their function in the context of a viral infection,
done best by reverse genetics. However, the original infectious
MV cDNA Ed-Tag, derived from a strain with an incompletely
documented passage history and containing segments of genetic
information form other strains, was recently shown to be de-
fective in IFN response control (Ballart et al., 1990; Combredet
et al., 2003; Ohno et al., 2004; Radecke et al., 1995). In
particular, its V protein function is impaired. Ohno et al.
identified by sequence comparisons two V protein amino acids
with IFN control function. One of them, tyrosine 110 (Y110) is
located in the common amino-terminal domain of P and V. The
other, cysteine 272 (C272), is one of the 7 conserved cysteines
in the zinc-binding carboxyl-terminal domain (Ohno et al.,
2004).
For the present study, we produced an infectious cDNAwith
fully functional P, V and C proteins, starting with a vial of
vaccine (Moraten strain). We then generated recombinant
viruses defective in either one or both C and V proteins. Even
viruses deficient in both proteins block the phosphorylation of
STAT1 and the nuclear translocation of STAT1 and 2 proteins
after IFN treatment, suggesting that another viral protein hasinnate immunity evasion function. We identified P as this protein,
and showed that tyrosine 110 in the common amino terminal
segment of the P/V proteins has an essential role in blocking IFN
function.
Results
A recombinant MV cDNA with equivalent coding capacity of a
vaccine strain and regularly spaced restriction sites
We generated a full-length cDNA clone with a coding
capacity equivalent to Moraten and Schwartz vaccine strains
based on cDNA copies of the N, P, M and F viral messenger
RNAs obtained after infection of Vero cells with a vial of
Moraten vaccine (Fig. 1A and Materials and methods). The
Moraten and Schwartz vaccines share an identical sequence in
spite of a nominally different origin (Parks et al., 2001a,
2001b). Since only a few amino acid differences, isolated in the
second half of the genome (H and L), existed between the
sequences of the Moraten and the original p(+)MV-NSe full-
length cDNA, we converted most of these changes (Radecke et
al., 1995). This conversion was executed on cassette vectors
and the corrected sequences were transferred to the low-copy-
number plasmid pBR322 backbone to facilitate propagating the
MV-genomic full-length cDNA in bacteria, as described
previously for the canine distemper virus reverse genetics
system (von Messling et al., 2003). The completed cDNA was
named pB(+)MVvac. With three exceptions, the coding
capacity of the MV genome in this plasmid is identical to that
of the Moraten and Schwartz strains. The three exceptions are
amino acids T331I, E429D and N1805S in the polymerase
gene. None of these residues are located in regions conserved
between paramyxoviral polymerases. Therefore, the coding
capacity of MVvac is equivalent, but not identical, to that of the
vaccine strain. We then recovered a MV from pB(+)MVvac
using the helper cells and system described in (Radecke et al.,
1995). This virus maintained the properties of the non-
recombinant Moraten strain (data not shown) with smaller
syncytia and 2–3 times higher titers than those observed for
MV Ed-Tag.
Recombinant MV deficient in either one or both C and V
proteins
Next we introduced mutations selectively preventing C
protein expression from pB(+)MVvac. A mutation converting
the start codon to ACG was combined with one converting
codon 6 to a stop codon (Fig. 1B, upper part, the two mutated
nucleotides are bolded). We rescued the virus, MVvacCko,
which grows to 25 times lower titers than the control virus
MVvac (3×105 tissue culture infective dose (TCID50)/ml
compared to 7.4×106 TCID50/ml). We analyzed viral protein
expression by immunoblot, confirming that these mutations
completely prevent C protein production (Fig. 1C, lane 3). A
reduction in titer and growth of a C-deficient virus expressing
also a hybrid P protein was measured, confirming an earlier
report (Devaux and Cattaneo, 2004).
Fig. 1. Vaccine-equivalent recombinant MV and derivatives thereof defective for the expression of the candidate IFN antagonist proteins. (A) Map of the MVvac
genome and flanking sequences in plasmid pB(+)MVvac (top) and of the inserts of the plasmids used for reconstitution of this genome (bottom). The five fragments on
the left were obtained by RT–PCR, the two on the right by mutagenesis of available clones. HδR (white circle): Hepatitis delta ribozyme, cutting precisely downstream
of the last nucleotide of the MV genome. Light grey: coding regions. Black circle (T7 promoter and T7 terminator): plasmid sequences transcription signals
determining synthesis and trimming of a full-length MVantigenome. The MVantigenome is represented with its 5′ end on the left and its six genes are indicated by
capital letters. (B) Schematic drawing illustrating the three proteins (C, P and V from the top) generated from the P gene, and the mutations silencing C and V protein
expression. The two mutations selectively ablating C protein expression (elimination of the start codon, ACG and introduction of one stop codon UAG) are indicated in
bold above the P gene nucleotide sequence (Cko). The two mutations selectively ablating V protein expression (one mutation in the editing sequence, G and
introduction of a stop codon UGA) are indicated in bold above the P gene sequence (Vko). The CVko virus has all four mutations (not shown). (C) Immunoblot analysis
of the P gene products expressed by the parental virus MVvac and its three derivatives MVvacCko, MVvacVko and MVvacCVko. Antisera against V protein (upper
panel) or against the C protein (lower panel) were used. Mock, uninfected cell control. N- and β-actin antibodies were used as controls of infection and protein load.
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RNA editing was co-introduced with another converting the
second codon of the V open reading frame into a UAG stop
codon (Fig. 1B lower part, the two mutated nucleotides are
bolded) (Schneider et al., 1997). The conserved sequence
UUAAAAAGGGCACAGA (the underlined polypurine tract is
essential for RNA editing) was mutated to UUAAAGAGGG-
CACUGA. We rescued the virus, MVvacVko, which grows to a
similar titer (4.9×106 TCID50/ml) as the control virus MVvac.
We analyzed viral protein expression by immunoblot, confirm-
ing that these mutations completely prevent V protein
production (Fig. 1C, lane 4).
To obtain recombinant virus MVvacCVko, the mutations
silencing C and V proteins expression were combined,
preventing both C and V proteins expression in the rescued
virus named, MVvacCVko (Fig. 1C, lane 5). This virus grew to
a 4×103 TCID50 titer almost 2000 times lower than the control
virus MVvac. MVvacCko, MVvacVko and MVvacCVko grew
with slower kinetics than MVvac, but retained their ability to
form syncytia.Even in absence of both C and V proteins, MV infection blocks
STAT protein translocation to the nucleus
We then investigated the relevance of the C and V proteins
for IFN response control. Cells were inoculated at a low (0.03)
multiplicity of infection (MOI) with the four recombinant MV
and analyzed for STAT protein translocation to the nucleus after
IFNα treatment (Figs. 2A–D, STAT1 [upper rows] and STAT2
[lower rows] are stained in red). Uninfected cells (not
expressing N, no green staining, left columns) provided internal
controls for STAT protein translocation. As expected, nuclear
translocation of both STAT1 and STAT2 was observed when the
cells were treated with IFNα (Figs. 2A–D, red [STAT panel] or
pink [merge panel] because of the blue DAPI counterstaining in
the nucleus in all non-green cells). As previously reported
(Palosaari et al., 2003), when cells were infected with the
MVvac control (Fig. 2A, infected cells express N and are
stained green), the translocation of the STATs proteins was
blocked and the red staining localized to the cytoplasm (Fig.
2A, cytoplasmic red staining in green fluorescent cells). A
Fig. 2. Prevention of IFN-induced STAT nuclear accumulation even in absence of C and V. Human HeLa cells were infected with recombinant viruses MVvac (A),
MVvacCko (B), MVvacVko (C), and MVvacCVko (D). Thirty hours post-infection cells were incubated with IFNα (2000 U/ml) for 30 min, fixed, permeabilized and
stained with antisera to nucleoprotein N (green), STAT1 (red, top rows) or STAT2 (red, lower rows) and DAPI (blue). Merge of the three staining are shown on the right
panels. Overlaps of red and green staining yield yellow, and overlaps of red and blue staining yield pink. Arrowheads point to infected cells and differentiate strong
(yellow) and moderate (white) inhibition of STAT translocation to the nucleus. (E) Enlarged details of an infected cell by MVvac showing cytoplasmic bodies (yellow
arrows).
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cytoplasmic bodies where they co-localized with MV N (Figs.
2A and E, merge panel, green and red merge to yellow staining
in the cytoplasm of infected cell, yellow arrows).
MVvacCko and MVvacVko retained STAT in the cytoplasm
as efficiently as MVvac and caused their redistribution in
cytoplasmic bodies (Figs. 2B and C, respectively). These results
suggest that in the absence of C or V protein, the other protein
can still interfere with the translocation of the STAT proteins
after IFN activation suggesting that these two proteins may have
a redundant function. Surprisingly, even MVvacCVko retained
both STAT proteins in the cytoplasm after IFNα activation (Fig.
2D). STAT1 translocation was fully inhibited after infection,
whereas STAT2 translocation was not completely blocked (Fig.
2D, compare cells labeled with yellow or white arrows).
Altogether, these results suggest that in the absence of C and V
another viral protein inhibits IFN signaling.
The P protein blocks STAT protein nuclear translocation and
IFN promoter activation
Since the P protein shares more than 200 residues with the V
protein, we assessed whether it retained STAT proteins in the
cytoplasm. To test this hypothesis we produced a vectorexpressing P but not C (pCG-P/Cko). Indeed, when cells
transfected with this vector were treated with IFNα, STAT1 was
retained in the cytoplasm (Fig. 3A, cytoplasmic red staining in
green fluorescent P-expressing cells). In adjacent non-trans-
fected cells, STAT1 localized to the nucleus (Fig. 3A, nuclear
red staining in non-green fluorescent cells). A similar but less
clear-cut effect was observed also for STAT2 after IFNα
activation: in certain P protein-expressing cells, STAT2 was
inefficiently, if at all, retained in the cytoplasm (Fig. 3A, pink
nuclei in cell marked with white arrows). The P protein co-
localized with STAT1 in cytoplasmic aggregates (Fig. 3D,
yellow arrows). These data indicate that the P protein is directly
or indirectly involved in the cytoplasmic sequestration of the
STAT proteins.
To quantitate the effect of P protein expression on the
activation of an IFN promoter, we compared its function to that
of V using an IFN-promoter-dependent luciferase assays. Cells
transfected with a plasmid expressing the P protein expressed
this reporter protein at 10- to 12-fold lower levels than cells
transfected with an empty vector (Fig. 3E, compare P/Cko with
empty). The V protein induced a 10- to 15-fold stronger reduc-
tion than the P protein (Fig. 3E, compare V/Cko with P/Cko),
suggesting that the V protein controls IFN signaling more
stringently than the P protein.
Fig. 3. Mutation of P protein tyrosine 110 influences inhibition of IFN-induced STAT nuclear accumulation. Human HeLa cells were transfected with an expression
plasmid encoding only the P protein (panel A, P/Cko), or only mutated P proteins (panels B and C, PY110H /Cko and PY110F /Cko). Thirty hours post-infection cells were
stimulated with IFNα (2000 U/ml) for 30 min. Cells were fixed, permeabilized and stained with antibody to P protein (green), STAT1 (red, top rows) or STAT2 (red,
lower rows) and DAPI (blue). Color codes for overlaps and arrows are as in Fig. 2. (D) Enlarged details of cell expressing P/Cko showing cytoplasmic bodies (yellow
arrows). (E) Measurement of IFN promoter activation through luciferase activity. Cells were transfected with the indicated or empty plasmids, along with pISRE-luc
and pCMV-RL (renilla luciferase as transfection control). After 24 h, the cells were treated or not for 18 h with IFNα, lysed, and the firefly and renilla luciferase
activities measured. Y-axis, relative light units (RLU) of firefly luciferase. Data represent the mean values±SD for triplicate samples. Transfection efficiencies of
different samples were normalized against the renilla luciferase activity, which is regulated by the CMV promoter and therefore unaffected by IFN treatment.
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retention
Ohno et al. reported that tyrosine 110 (Y110) and cysteine
272 (C272) of the V protein are implicated in blocking IFN
signal transduction (Ohno et al., 2004). Since Y110 is located in
the common domain of P and V proteins, we assessed whether P
residue 110 also affects STAT protein cytoplasmic retention
function. Indeed, in transfected cells expressing PY110H the
STAT1 and STAT2 proteins translocated to the nucleus (Fig. 3B,
pink nuclei in merge panels), as STAT proteins did in neigh-
boring non-transfected cells. Thus the P protein Y110, like the V
protein Y110, may contribute to the control of IFN response.
We then considered the possibility that the exchange of an
aromatic (Y) with a basic (H) amino acid induced a
conformational change in the P protein causing loss of function.
We produced an expression plasmid coding for a P protein with
the other aromatic residue F in place of Y (PY110F). Similar
expression level of all full-length P proteins (P, PY110H and
PY110F) was observed by immunoblot analysis after transfection
(data not shown) and cells with similar levels of P expression
were compared (Figs. 3A–C, similar level of green fluorescence
in P-expressing cells). In cells expressing these proteins (PY110H
and PY110F), the STAT1 and STAT2 proteins translocated to the
nucleus (Fig. 3C, pink nuclei in merge panels), indicating that
Y110 is necessary for function. Moreover, after transfection of293 cells with the two mutants PY110H and PY110F, luciferase
expression increased by 5- and 3-fold, respectively, compared to
cells transfected with standard P (Fig. 3E, compare PY110H/Cko
and PY110F/Cko with P/Cko) indicating partial recovery of IFN
promoter function.
We then assessed, in the context of a MV infection,
whether a virus defective for expression of both C and V
proteins and with a mutated Y110H residue lost STAT1 and
STAT2 cytoplasmic retention function. We rescued such a virus,
named it MVvacPY110HCVko, and infected cells at a lowMOI to
be able to compare the localization of STAT1 and STAT2 in
infected and neighboring non-infected cells. In infected and non-
infected cells STAT1 and STAT2 translocated to the nucleus
(Fig. 4A, STAT and merge panels). Thus the introduction of a
single mutation (Y110H) in the P gene of a C and V deficient
virus impaired its ability to control STAT protein translocation.
MV-NSe cannot retain STAT proteins in the cytoplasm
Viruses generated from the original MV Ed-Tag infectious
cDNA or from its derivative MV-NSe (NSe means NarI-and
SpeI-eliminated; the corresponding cDNA has additional
unique restriction sites that facilitate engineering) share
mutations C272R in the V carboxyl-terminal domain and
Y110H in the common amino-terminal domain of P and V
(Radecke et al., 1995; Singh and Billeter, 1999). Since it was
Fig. 4. Recombinant viruses expressing mutated P proteins do not block STAT1
and STAT2 nuclear translocation after IFNα activation. Human HeLa cells were
infected with recombinant viruses MVvacPY110HCVko (A) or MV-NSe (B) and
stimulated with IFNα for 30 min. Cells were fixed, permeabilized and stained
with antisera to nucleoprotein N (green), STAT1 (red, top rows) or STAT2 (red,
lower rows) and DAPI (blue). Overlaps of red and green staining yield yellow
and overlaps of red and blue staining yield pink.
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promoter activation (Ohno et al., 2004), we asked whether MV-
NSe could control STAT proteins nuclear translocation. Cells
were inoculated at a low MOI to compare infected and
neighboring non-infected cells. MV-NSe, which is more
fusogenic than the Moraten strain or MVvac as documented
by the large syncytia (Fig. 4B), was unable to efficiently retain
STAT1 and STAT2 in the cytoplasm (Fig. 4B). Thus by this
criterion the competence of MV-NSe to interfere with innate
immunity is strongly impaired, implying that MV-NSe and MV
Ed-tag are more attenuated than the Moraten vaccine strain.
Modulation of STAT1 and STAT2 phosphorylation
Previous work suggested that the MV wild-type IC-B strain
P protein could block IFN signaling (Ohno et al., 2004). Our
data confirmed that the P protein of a vaccine strain of MV can
also block IFN signaling and that this inhibition correlates with
cytoplasmic retention of STAT proteins. Since our work also
suggested that P cooperates with C and V while interfering with
the activation of the innate immune response, we analyzed its
interactions with the IFN signaling pathway in the context of
viral infections. We characterized and compared the early
phases of IFNα signal transduction after infection with a virus
that express neither C nor V protein (MVvacCVko) with those
of an equivalent virus that additionally carries the PY110H
mutation. We monitored by immunoblot the phosphorylationlevels of STAT1 and STAT2. Since HeLa cells produce low
levels of IFN, complicating the analysis of infection, we used
Vero.hSLAM cells that are defective for IFN production. These
cells were infected at a MOI of 0.5 with MVvac, MVvacCVko
and MVvacPY110HCVko for 20 h and then treated for 10 or
20 min with IFNα. Non-treated cells infected or not with
MVvac were used as controls. Analysis of the viral P, C, V and
N proteins (Fig. 5A, bottom panels) confirmed virus identity,
and showed that MVvacCVko, and especially MVvacP-
Y110HCVko, replicate at lower levels than MVvac.
In Vero.hSLAM cells, induction of STAT1 and STAT2
phosphorylation was strong after 10 and even stronger after
20 min of treatment with IFNα (Fig. 5A, STAT1-P and STAT-2P
blots, compare IFN-treated cells in lanes 1–2 with non-treated
cells in lane 9). Infection with MVvac completely inhibited
STAT1 phosphorylation, and infection with MVvacCVko
strongly reduced it (Fig. 5A, STAT1-P blot, compare lanes
3–4 with 1–2 and 5–6). Thus even in the absence of C and V the
virus is still able to strongly inhibit STAT1 phosphorylation. A
strong reduction of STAT2 phosphorylation occurred after
infection with MVvac, but in the absence of C and V, STAT2
phosphorylation was only mildly reduced, suggesting that the P
protein has a minor effect on the inhibition of STAT2
phosphorylation (Fig. 5A, STAT2-P blots). Decrease in STAT
phosphorylated protein was not due to degradation: the total
amount of unphosphorylated STAT proteins remained the same
in infected cells and non-infected cells (Fig. 5A, STAT1 and
STAT2 blots). These results show that in the context of a fully
competent virus infection, as well as with a virus unable to
express C and V protein, the IFN signaling inhibition results
from an alteration of STAT1 and STAT2 protein phosphoryla-
tion, and that P is strongly involved in the inhibition of STAT1
phosphorylation.
A role for P protein tyrosine 110 in blocking STAT1
phosphorylation
We then assessed the STAT1 protein phosphorylation status
after infection with MVvacPY110HCVko, a virus with the Y110H
mutation in the P protein. After 10 or 20 min of IFNα treatment,
levels of STAT1 phosphorylation were close to that of mock-
infected cells (Fig. 5A, STAT1-P blot, compare lanes 7–8 with
lanes 1–2). On the other hand, the phosphorylation levels of
STAT2, were similar to those observed after infection with
MVvacCVko (Fig. 5A, STAT2-P blot, compare lanes 7–8 with
lanes 5–6).
In order to confirm the effect of Y110 on STAT1
phosphorylation, we performed immunostaining of phosphory-
lated STAT1 on infected and non-infected cells by confocal
microscopy. Vero.hSLAM or HeLa cells were infected for
20 h with MVvacCVko or MVvacPY110HCVko, treated with
IFNα, and stained with an anti-phospho-STAT1 antibody
(Figs. 5B and C). As expected, nuclear translocation of
phospho-STAT1 was observed when uninfected cells were
treated with IFNα (Figs. 5B and C, red [STAT panel] or pink
[merge panel]). In cells on the same slide infected with
MVvacCVko (Fig. 5B, infected cells express N and are stained
Fig. 5. Analysis of STAT1 and STAT2 protein phosphorylation during infection with viruses defective for expression of P gene products. (A) Immunoblot analysis of
Vero.hSLAM cells infected with MVvac (lanes 3, 4 and 10), MVvacCVko (lanes 5 and 6) and MVvacPY110HCVko (lanes 7 and 8) or mock-infected (lanes 1, 2 and 9).
Twenty hours post-infection, cells were either treated with IFNα (lanes 1–8) for 10 or 20 min as indicated at the top of the blots or left untreated (lanes 9 and 10).
Membranes were blotted with antibodies against STAT proteins or MV proteins, as indicated on the right. Actin was a loading control. (B and C) Simian Vero.hSLAM
(Vero, top rows) or human HeLa (bottom rows) cells were infected with recombinant viruses MVvacCVko (B) or MVvacPY110HCVko (C). Twenty hours post-infection
cells were incubated with IFNα (2000 U/ml) for 30 min, fixed, permeabilized and stained with antisera to nucleoprotein N (green), phospho-STAT1 (red) and DAPI
(blue). Merge of the three staining are shown on the right panels.
78 P. Devaux et al. / Virology 360 (2007) 72–83green) or MVvac control (not shown), red staining of
phospho-STAT1 was observed neither in the nucleus nor in
the cytoplasm (Fig. 5B, no red staining in green fluorescent
cells). Similar patterns of staining were observed after
infection of Vero.hSLAM or HeLa cells (Fig. 5B, top and
bottom row, respectively). These results confirm the immuno-
blot blot data indicating that during infection by MV and in
the absence of the C and V proteins, the virus blocks the
phosphorylation of STAT1 protein in response to IFNα
activation. After infection with MVvacPY110HCVko, phos-
phorylated STAT1 protein localized to the nucleus in infected
cells (Fig. 5C, nuclear red staining in green fluorescent cells),
confirming that Y110 is essential for this P protein function.
Taken together, these results indicate that all three proteins
produced by the MV P gene synergize to control IFN signaling.
Discussion
MV P gene products and innate immunity evasion
We demonstrate here that even without C and V expression,
MV efficiently blocks the nuclear translocation of STAT
proteins after IFN activation. This observation confirms therole of P protein in inhibiting the cellular immune response:
using an IFN-promoter activation assay, Ohno et al. previously
noted that both Vand its isolated P-colinear amino-terminal half
have IFN transcription inhibition function (Ohno et al., 2004).
We have focused here on the nuclear translocation and
phosphorylation of the STAT proteins after IFN activation,
and shown that the P protein blocks STAT1 protein phosphor-
ylation. In contrast, the V protein blocks the translocation of the
STAT proteins without interfering with their phosphorylation
(Palosaari et al., 2003).
The function of MV C and V proteins was initially studied
based on viruses derived from the original MV cDNA Ed-Tag
made defective for C or V protein expression (Radecke and
Billeter, 1996; Radecke et al., 1995; Schneider et al., 1997). The
spread of these viruses was compared with that of the parental
strain in peripheral blood mononuclear cells (Escoffier et al.,
1999), in human thymus/liver implants engrafted in SCID mice
(Valsamakis et al., 1998), in cotton rats (Tober et al., 1998), and
in genetically modified mice (Mrkic et al., 2000; Patterson et al.,
2000). In all these systems, effects of the abrogation of C and V
protein expression were monitored.
Since the V protein of the original MV cDNA is not fully
functional, its importance for viral spread may have been
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abrogated virus with its parental V-diminished strain. On the
other hand, the original C-defective virus is also V- and P-
diminished, a fact that may have led to an over-estimation of the
importance of C for host defense control (Radecke and Billeter,
1996; Shaffer et al., 2003). Nevertheless, a recent study based
on a cDNA-derived wild type MVand its C-defective derivative
indicated the importance of C for virus spread in macaque
lymphatic tissue (Takeuchi et al., 2005). The importance of
Morbillivirus C and V for pathogenesis was recently compared
in ferrets infected with canine distemper virus (von Messling et
al., 2006). In these animals V sustains swift invasion of mucosal
tissue and lymphatic organs, whereas C is necessary only for
subsequent infection phases.
A general role for Paramyxovirus P protein in innate immunity
evasion
The P protein of the Nipah virus controls the IFN response
together with the V and W protein expressed from edited
transcripts (Harcourt et al., 2000; Shaw et al., 2004). These
proteins have a common 407-residue amino-terminal domain
but distinct carboxyl-terminal domains. The shared amino-
terminal domain of these three proteins blocks STAT1
phosphorylation (Park et al., 2003; Rodriguez et al., 2002;
Shaw et al., 2004). Recently it was also shown that the P protein
of rabies virus has innate immunity control function (Brzozka et
al., 2005, 2006; Vidy et al., 2005). Altogether these studies raise
the possibility that the P protein of many negative strand RNA
viruses may have host immune response control function.
The main P protein function is to serve as viral polymerase
cofactor. In addition, P prevents illegitimate N protein self-
assembly and its nuclear translocation (Curran et al., 1995;
Huber et al., 1991; Spehner et al., 1997). Towards this, the P
protein amino-terminal region, which is unstructured in vitro,
associates with N (Curran et al., 1995; Karlin et al., 2002;
Kingston et al., 2004). Our results indicate that MV P co-
localizes with the STAT proteins in the cytoplasm, and is
concentrated in cytoplasmic bodies, extending the V-protein
observations made by Palosaari et al. (Palosaari et al., 2003). It
was also shown that the carboxyl-terminal domain of P binds a
RING-H2 domain of the ubiquitin E3 ligase PIRH2 (Chen et al.,
2005). The above data, and the fact that cytoplasmic bodies
form even in the absence of C and V, suggest that P may be
involved in appropriating components of the cellular machineryFig. 6. Sequence alignment of amino acids 81–150 in the common amino-terminal se
sequence are: AAF85668.1 (measles), CAA48389.1 (Rinderpest), AAQ96296.1 (cani
ruminants), and CAE55654.1 (dolphin morbillivirus). Sequence alignments were pe
(Altschul et al., 1997) and the ClustalW program. Homologous sequences are boxed. “
substitutions, respectively.for use in viral transcription and replication while also blocking
innate immunity. Cytoplasmic bodies, which have been
observed for other Paramyxoviruses like SV5 (Fearns et al.,
1994), HPIV2 (Nishio et al., 1996), respiratory syncitial virus
(Garcia et al., 1993), Sendai virus (Portner et al., 1986) and
mumps virus (Ulane et al., 2003) may be the locale where
Paramyxoviruses replicate.
A short conserved region downstream of the Morbillivirus P
protein tyrosine 110
Tyrosine 110 in the common segment of the P and V proteins
(a histidine in the MVNSe virus that cannot control innate
immunity) is the first of six amino acids almost perfectly
conserved between six morbilliviruses (Fig. 6). The hexapep-
tide Y(Y/H)VYDH is preceded by a variable region (amino
acids 80–109) and followed by a region of intermediate
conservation (amino acids 116–150). On the other hand, the
hexapeptide is not conserved in other Paramyxovirus P
sequences (data not shown). The strong conservation within
the Morbillivirus family suggests that the P protein from the
different family members may have a function similar to MV-P
and that this hexapeptide may interact with a conserved cellular
partner. Indeed, while this paper was in preparation we learned
that the P protein of Rinderpest virus also blocks type I and type
II IFN responses (Nanda and Baron, 2006).
Finally, several recombinant MV have been produced to
support oncolytic therapy studies including a virus currently
used in a clinical trial of ovarian cancer (Springfeld et al., 2005;
E. Galanis, personal communication). All these viruses have the
P/V protein Y110H mutation, as well as the V protein C272R
mutation. Thus, since two components of the system modulat-
ing innate immunity are defective, these viruses may replicate
efficiently only in patients with tumors that have a defective
IFN response system.
Materials and methods
Cells and viruses
Vero (African green monkey kidney), Vero.hSLAM (Vero
cells expressing human SLAM, kindly provided by Y. Yanagi)
and HeLa cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) containing 10% fetal bovine serum
(FBS), penicillin, and streptomycin at 37 °C and 5% CO2.gment of sixMorbilliviruses P and V proteins. GenBank numbers for each virus
ne distemper), BAA01203.1 (phocine distemper), CAH61253.1 (Peste des petits
rformed at the SIB using the BLAST network service, NCBI Blast 2 software
*”: residues identical in all sequences. “:” and “.”: conserved and semi-conserved
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were grown in DMEM-10% in the presence of 1.2 mg/ml
G418.
To prepare virus stocks, Vero.hSLAM cells were infected at a
MOI of 0.03 TCID50/cell with the relevant virus and incubated
at 32 °C. Cells were scraped in Opti-MEM (Gibco), and
particles released by two freeze–thaw cycles. Titers were
determined by 50% TCID50 titration on Vero.hSLAM cells
according to the Spearman–Kärber method (Kärber, 1931).
Construction of a vaccine-equivalent infectious cDNA
To obtain a full-length cDNA with a vaccine-equivalent
coding capacity, a strategy based on cDNA clones for the first
half of the genome, and on corrections of variant residues for the
second half of the genome, was adopted (Fig. 1A). To generate
cDNAs, RNAwas isolated fromVero cells infected with a vial of
the Moraten vaccine (Merck, West Point, PA) using the RNeasy
RNA isolation kit (Qiagen, Hilden, Germany). The RNA was
reverse transcribed using Superscript (Invitrogen, Carlsbad,
CA), and five overlapping fragments (Fig. 1A, left half, blacks
bars) were PCR amplified (Expand High Fidelity PCR system,
Roche Biochemicals, Indianapolis, IN) and cloned into Topo
cloning vectors (Invitrogen). The T7 promoter sequence was
added to the end of the first fragment that included the entire N
gene and part of the P gene (Fig. 1A, left part, SfiI–SacII
fragment). The second fragment included the remainder of the P
gene up the SpeI site (SacII–SpeI fragment). The SpeI site was
subsequently destroyed by site-directed mutagenesis leaving a
unique SpeI site after H gene. The third fragment extended from
SpeI to NarI including the entire M gene, and the fourth and the
fifth fragments covered the F gene between NarI and HpaI, and
HpaI and PacI, respectively. At least 3 clones of each fragment
were sequenced (ABI PRISM 377 DNA Sequencer, Perkin-
Elmer Applied Biosystems). The consensus sequence was
identical with GenBank AE266287. Only clones that corre-
sponded exactly to this consensus sequence were used to
assemble the full-length cDNA clone (Fig. 1A).
The mutagenized H and L fragments were subsequently
inserted into the genome, yielding pB(+)MVvac. All coding
mutations in the H gene have been corrected, and all but three
coding mutations in the L gene. Thus the MV genome in pB(+)
MVvac has these coding differences from the Moraten and
Schwartz strains (AF266287 and AF266291) in the L gene:
T331I, E429D and N1805S. In addition, several non-coding
differences were left in the H and the L genes and introduced
into other genes to add or eliminate restriction sites that allowed
easy exchange of expression cassettes covering approximately
one gene (Fig. 1).
C- or V-defective full-length cDNAs
Site-directed mutagenesis was performed using the quick-
change system (Stratagene, La Jolla, CA) on a cassette vector
covering the P gene sequence. To produce pB(+)MVvacVko and
pB(+)MVvacCko, site-directed mutagenesis was performed on
pCGNheI-MVvac-HpaI (Devaux, unpublished) using followingprimers: 5′-CAGCACTTCCGGGACACCCATTAAAGAGG-
GCACTGACGCGAGATTAGCCTCATTTGG and 5′-GGCA-
GAAGAGCAGGCACGCCACGTCAAAAACGGACTA-
GAATGCATCCGGGCTCTCAAGG respectively. The full-
length cDNA pB(+)MVvacVko and pB(+)MVvacCko were
obtained by moving a mutated SfiI–NarI fragment into the
full-length cDNA pB(+)MVvac. To produce pB(+)
MVvacCVko, two successive rounds of mutagenesis were
performed on pCGNheI-MVvac-HpaI. To produce pB(+)
MVvacPY110HCVko, a third round of site-directed mutagen-
esis was performed to exchange the codon TAT (tyrosine
110) by the codon CAT (histidine). The full-length cDNA
pB(+)MVvacPY110HCVko was then obtained by exchanging
the SfiI–NarI fragment from the full-length cDNA pB(+)
MVvac with the mutated SfiI–NarI fragment. The integrity
of the full-length constructs was verified by sequencing.
Expression plasmids
An expression plasmid coding for the P protein but not for
the C protein (P/Cko) was produced by PCR. The cDNA coding
for the P/Cko protein was obtained from the pB(+)MVvacCko
full-length vector using the following sense and antisense
primers: 5′-CATCATCCCGCGGCCGCTTAATTAAATGGCA-
GAAGAGCAGGCACGC and 5′-GATAGATGATGTC-
GACCTCGAGCTACTTCATTATTATCTTCATCAGC. Two
restriction sites, PacI and SalI (underlined) were introduced
upstream and downstream of the P open reading frame (ORF) to
facilitate subsequent subcloning in the pCG vector to obtain the
pCG-P/Cko expression plasmid.
The mutated pCG-PY110H/Cko and pCG-PY110F/Cko expres-
sion vectors were obtained by site-directed mutagenesis, where
the codon TAT (tyrosine 110), was exchanged by the codon
CAT (histidine) or TTT (phenylalanine). The integrity of all
constructs was verified by sequencing.
Recombinant virus recovery
Recombinant MVs were generated as described by Radecke
et al. (1995). Briefly, the helper cell line 293-3-46 stably
expressing MV-N, MV-P, and T7 polymerase was transfected
by calcium phosphate precipitation using the ProFection kit
(Promega, Madison, WI) with two plasmids, one coding for the
relevant MV genome and the other for the MV polymerase
(pEMCLa). Three days after transfection, the helper cells were
overlaid on Vero.hSLAM cells and appearance of infectious
centers was monitored, then single syncytia were picked and
propagated on Vero.hSLAM cells.
Western blot analysis of cell extracts
Cells (105) were infected with an MOI of 0.5 for 20 h later or
when 70–80% of the nuclei were found in syncytia, incubated
or not with IFNα (2000 U/ml [Serotec, Oxford U.K.]) for 10 or
20 min at 37 °C. The cells were then washed in phosphate-
buffered saline (PBS), incubated for 10 min at 4 °C in cell lysis
buffer (Cell Signaling, Beverly, MA) containing protease
81P. Devaux et al. / Virology 360 (2007) 72–83inhibitors (Protease inhibitor cocktail set I [Calbiochem, La
Jolla, CA]), and phosphatase inhibitors (Phosphatase inhibitor
cocktail set II [Calbiochem]) and centrifuged at 5000×g for
15 min at 4 °C. The supernatants were denatured with urea
buffer (200 mM Tris–HCl [pH 6.8]; 8 M urea; 0.1 mM EDTA
[pH 8]; 5% sodium dodecyl sulfate [SDS]; 0.03% bromophenol
blue) containing 1.5% dithiothreitol for 10 min at 90 °C.
Samples were fractionated on 4–15% SDS–polyacrylamide
gels (Biorad, Hercules, CA), blotted to polyvinylidene difluor-
ide membranes (Immobilon-P [Millipore, Billerica, MA]) and
subjected to enhanced chemiluminescence detection using the
antibodies indicated.
Luciferase assays
Cells (293 line, 2×105 per well) were plated in 24-well
plates. One day later they were transfected with (per well)
0.05 μg pRL-CMV (Promega) plus 0.375 μg of pISRE-luc
(Stratagene) plus 0.375 μg of either pCG, pCG-P/Cko, pCG-
PY110H/Cko, pCG-PY110F/Cko or pCG-V/Cko. Transfection was
performed with Lipofectamine 2000 (Invitrogen) according to
the manufacturer's protocol. After 24 h, IFNα was added to the
medium at 2000 U/ml, the cells were incubated for additional
18 h. The luciferase activity was measured using Dual-Glo
Luciferase Assay System according to the manufacturer's
protocol (Promega) and a TopCountNXT luminescence counter
(Packard Instrument Company, Meriden, CT)). Each transfec-
tion was carried out in triplicate in each experiment, and each
experiment was performed at least twice. Variations in the
transfection efficiency were accounted for by calculating the
ratio of firefly luciferase activity to renilla luciferase activity in
any one sample.
Antibodies
A mouse monoclonal anti-P antibody was kindly provided
by D. Gerlier. The commercially available FITC-labeled mouse
monoclonal anti-N antibody (Chemicon, Tumecula, CA) was
used. For Vand C protein detection, rabbit anti-peptide antisera
recognizing the 14 carboxyl-terminal amino acids of the V
protein, or the 12 carboxyl-terminal amino acids of the C
protein were used (Devaux and Cattaneo, 2004). Rabbit
antibodies directed against STAT1α p91 (C-24) or STAT2 (C-
20) for confocal analysis, and mouse antibodies against
STAT1α p91 (C-111) or STAT2 (A-7) for immunoblot analysis
were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Rabbit anti-phospho-STAT1 (Tyr701) and STAT2
(Tyr689) were obtained from Upstate Biotechnology (Lake
Placid, NY). Rabbit anti-phospho-STAT1 (Tyr701) for immu-
nofluorescence was obtained from Cell Signaling Technology
(Beverly, MA).
Confocal microscopy
Cells (3×104 cells in chamber slides [Lab Teck II Chamber
Slide System, Nalge Nunc International Corp, Naperville, IL])
were either infected with MV at a MOI of 0.03 or transfectedwith expression plasmid coding for P protein according to
manufacturer recommendation (Lipofectamine 2000, Invitro-
gen). Thirty hours post infection or transfection, cells were
treated with IFNα (2000 U/ml) for 30 min at 37 °C. Cells were
washed once with PBS and fixed with PBS–2% paraformalde-
hyde (PFA). Cells were permeabilized with PBS–2% PFA–
0.1% Triton for 20 min, washed with PBS, and incubated for 1 h
in blocking solution (PBS–2% FCS). Alternatively, when the
cells were stained with anti-phospho-STAT1 antibody, the cells
were fixed and permeabilized for 10 min in cold methanol at
4 °C. Cells were then immunostained for STAT1, STAT2 or
STAT1-P proteins and for N or P proteins. Incubations were
performed in PBS–2% FCS for 1 h at 37 °C for most of the
antibodies and over night at 4 °C for STAT1-P, and 5 washes
were performed after incubation with primary and secondary
antibodies. After the last washes, cells were mounted with
Vectashield containing DAPI (Vector Laboratories, Burlingame,
CA) and analyzed with a Zeiss LSM 510 confocal microscope.
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